Modulating granulocytic myeloid-derived suppressor cell (G-MDSC) metabolic activity to promote Staphylococcus aureus biofilm clearance

调节粒细胞骨髓源性抑制细胞 (G-MDSC) 代谢活性以促进金黄色葡萄球菌生物膜清除

基本信息

  • 批准号:
    10738662
  • 负责人:
  • 金额:
    $ 23.03万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-06-15 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

Staphylococcus aureus (S. aureus) is a leading cause of biofilm-associated prosthetic joint infection (PJI) characterized by antibiotic tolerance and evasion of immune-mediated clearance. Our laboratory has established a critical role for granulocytic myeloid-derived suppressor cells (G-MDSCs), a pathologically activated neutrophil precursor, in attenuating monocyte/macrophage (MФ) proinflammatory properties and neutrophil bactericidal activity that leads to S. aureus biofilm persistence. The metabolic attributes of leukocytes are intimately linked with their inflammatory properties, relationships encompassing the emerging field of immunometabolism. This has been best described for MФs, where biases towards aerobic glycolysis or oxidative phosphorylation (OxPhos) dictate pro- vs. anti-inflammatory activity, respectively. In contrast, little information is available regarding the metabolic tendencies of G-MDSCs during infection and our preliminary studies are the first to demonstrate that G-MDSCs exhibit a glycolytic bias following S. aureus biofilm exposure in vitro and in vivo. Importantly, blocking glycolysis in G-MDSCs attenuated their suppressive activity resulting in decreased biofilm burden in vivo. This provides proof-of-concept that targeting G-MDSC metabolism is a tractable and novel approach to promote biofilm clearance. Recent studies have revealed that mitochondria can directly traffic between cells in vitro and in vivo via tunneling nanotubes (TNTs), where mitochondrial transfer in recipient cells promotes their OxPhos activity. However, most of these reports examined TNT-mediated mitochondrial transfer between mesenchymal stem cells and endothelial cells or cardiomyocytes, whereas this mechanism of intercellular metabolic rewiring has not been explored in the context of MФ-G-MDSC crosstalk. These studies will leverage MФs as a source of mitochondria for reprogramming G-MDSC metabolism, which originated from our prior work showing that MФ adoptive transfer reduced S. aureus biofilm burden in vivo. Indeed, our preliminary data support this innovative concept, where MФs transferred their mitochondria to G-MDSCs in a cell contact-dependent manner, which skewed G-MDSC metabolism towards OxPhos. This R21 revision will investigate the hypothesis that increasing mitochondrial abundance in G-MDSCs will result in metabolic reprogramming from glycolysis to an OxPhos bias coincident with diminished immune suppressive activity, resulting in improved biofilm clearance. Understanding how mitochondrial transfer from MФs can reprogram G- MDSC metabolism will be examined leveraging natural transfer and exogenous mitochondrial treatment paradigms in the following Specific Aims. 1) Identify the functional implications of mitochondrial transfer on G- MDSC anti-inflammatory activity and 2) Determine whether augmenting G-MDSC mitochondrial activity improves S. aureus clearance during PJI. These studies will inform our long-term goal of targeting critical metabolic nodes to reprogram aberrant leukocyte anti-inflammatory responses to eradicate biofilm together with antibiotics.
金黄色葡萄球菌(S.金黄色葡萄球菌)是导致生物膜相关性人工关节感染(PJI)的主要原因 其特征在于抗生素耐受性和免疫介导清除的逃避。我们的实验室已经建立了 粒细胞性髓源性抑制细胞(G-MDSCs),一种病理性活化中性粒细胞的关键作用 前体,在减弱单核细胞/巨噬细胞(MФ)促炎特性和嗜中性粒细胞杀菌中的作用 导致S.金黄色葡萄球菌生物膜持久性。白细胞的代谢属性与 与它们的炎性特性的关系包括免疫代谢的新兴领域。这 最好描述为MФs,其中偏向需氧糖酵解或氧化磷酸化 (OxPhos)分别指示促炎活性和抗炎活性。相比之下,几乎没有可用的信息 关于G-MDSCs在感染过程中的代谢趋势,我们的初步研究首次 证明G-MDSCs在S.金黄色葡萄球菌生物膜体外和体内暴露。 重要的是,阻断G-MDSCs中的糖酵解减弱了其抑制活性,导致生物膜减少 体内负荷。这提供了以G-MDSC代谢为靶点的概念证明,是一种易处理的新方法。 促进生物被膜清除方法。最近的研究表明线粒体可以直接运输 通过隧道纳米管(TNTs)在体外和体内细胞之间进行,其中受体细胞中的线粒体转移 促进其OxPhos活性。然而,大多数这些报告检查了TNT介导的线粒体转移 间充质干细胞和内皮细胞或心肌细胞之间的相互作用,而这种机制 还没有在MФ-G-MDSC串扰的背景下探索细胞间代谢的重新布线。这些研究 将利用MФs作为线粒体的来源,对G-MDSC代谢进行重编程,这源于 我们先前的工作表明MФ过继转移降低了S。金黄色葡萄球菌生物膜负荷。的确,我们的 初步数据支持这一创新概念,即MФs将其线粒体转移到G-MDSCs, 细胞接触依赖性方式,使G-MDSC代谢偏向OxPhos。本R21修订版将 研究G-MDSCs中线粒体丰度增加将导致代谢 从糖酵解重编程为OxPhos偏性与免疫抑制活性降低一致, 导致生物膜清除率提高。了解MФs的线粒体转移如何对G- 将利用自然转移和外源性线粒体处理检查MDSC代谢 在以下具体目标中的范例。1)确定线粒体转移对G-细胞凋亡的功能影响 MDSC的抗炎活性和2)确定增加G-MDSC线粒体活性是否改善 S.在PJI期间清除金黄色葡萄球菌。这些研究将为我们的长期目标提供信息,即靶向关键代谢节点 以与抗生素一起根除生物膜。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tammy L Kielian其他文献

Tammy L Kielian的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tammy L Kielian', 18)}}的其他基金

T cell-innate immune crosstalk regulates Staphylococcus aureus craniotomy infection
T细胞先天免疫串扰调节金黄色葡萄球菌开颅感染
  • 批准号:
    10590634
  • 财政年份:
    2022
  • 资助金额:
    $ 23.03万
  • 项目类别:
Immune mechanisms that promote S. aureus persistence during craniotomy-associated biofilm infection
开颅手术相关生物膜感染期间促进金黄色葡萄球菌持续存在的免疫机制
  • 批准号:
    9896877
  • 财政年份:
    2018
  • 资助金额:
    $ 23.03万
  • 项目类别:
Immune mechanisms that promote S. aureus persistence during craniotomy-associated biofilm infection
开颅手术相关生物膜感染期间促进金黄色葡萄球菌持续存在的免疫机制
  • 批准号:
    10375439
  • 财政年份:
    2018
  • 资助金额:
    $ 23.03万
  • 项目类别:
Therapeutic targeting of aberrant glial function during Juvenile Batten Disease
幼年巴顿病期间异常神经胶质功能的治疗靶向
  • 批准号:
    8660113
  • 财政年份:
    2014
  • 资助金额:
    $ 23.03万
  • 项目类别:
Therapeutic targeting of aberrant glial function during Juvenile Batten Disease
幼年巴顿病期间异常神经胶质功能的治疗靶向
  • 批准号:
    8788453
  • 财政年份:
    2014
  • 资助金额:
    $ 23.03万
  • 项目类别:
Contribution of extracellular enzymes to Staphylococcus aureus biofilm development
胞外酶对金黄色葡萄球菌生物膜发育的贡献
  • 批准号:
    10665029
  • 财政年份:
    2009
  • 资助金额:
    $ 23.03万
  • 项目类别:
Innate Immunity to S. aureus biofilm
对金黄色葡萄球菌生物膜的先天免疫
  • 批准号:
    7750241
  • 财政年份:
    2009
  • 资助金额:
    $ 23.03万
  • 项目类别:
The Role of Nuclease in Biofilm Development and Disease
核酸酶在生物膜发育和疾病中的作用
  • 批准号:
    7750239
  • 财政年份:
    2009
  • 资助金额:
    $ 23.03万
  • 项目类别:
Innate Immune Response to S. aureus Biofilm
对金黄色葡萄球菌生物膜的先天免疫反应
  • 批准号:
    10665032
  • 财政年份:
    2009
  • 资助金额:
    $ 23.03万
  • 项目类别:
Contribution of extracellular enzymes to Staphylococcus aureus biofilm development
胞外酶对金黄色葡萄球菌生物膜发育的贡献
  • 批准号:
    10461797
  • 财政年份:
    2009
  • 资助金额:
    $ 23.03万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 23.03万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 23.03万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 23.03万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 23.03万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 23.03万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 23.03万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 23.03万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 23.03万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 23.03万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 23.03万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了